Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine.
Current cancer immunotherapies predominantly rely on CD8(+) T cells to fight against tumors. However accumulative evidence showed that proinflammatory CD4(+) helper T cells are critical determinants of effective antitumor immunity. The utilization of universal tumor-reactive helper peptides from telomerase represents a powerful approach to the fully use of CD4(+) T cell-based immunotherapy.
INSERM; Unité Mixte de Recherche 1098; Besançon, France; Etablissement Français du Sang de Bourgogne Franche-Comté; UMR1098; Besançon cedex, France; Université de Franche-Comté; UMR1098 ; SFR IBCT; Besançon, France; CHRU de Besançon ; Service d'Oncologie; Besançon, France.
Olivier
O
Adotévi
Magalie
M
Dosset
Jeanne
J
Galaine
Laurent
L
Beziaud
Yann
Y
Godet
Christophe
C
Borg
D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000628:therapy*; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology*; D019098:Telomerase / Q000276:immunology*; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000276:immunology*
D019496:Cancer Vaccines; D022223:Vaccines, Subunit; D019098:Telomerase
CD4 T cell; cancer vaccine; helper peptide; telomerase